Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by APXiMAB™, the Company’s proprietary antibody drug discovery platform.

Register for Details

For more details on financing and valuation for Apexigen, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Apexigen's ticker symbol?


What is Apexigen's stock price?

0.3851 as of 8/22/23

Apexigen Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
3/24/2020 Series C $127.86MM raised $XXX.XX $XXX.XX
8/8/2018 Series B $15MM raised $XXX.XX $XXX.XX
8/8/2013 Series A-1 and A-2 $22.52MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Apexigen

Forge green plus iconForge green minus icon

What is Apexigen funding to date?

Apexigen has raised $165.38MM to date.
Forge green plus iconForge green minus icon

When was Apexigen founded?

Apexigen was founded in 2010.
Updated on: Jun 12, 2022